News Wire
Glenmark Pharmaceuticals and SaNOtize Announce Peer Reviewed Publication of Its Phase 3 Clinical Trials on SaNOtize’s Novel Nitric Oxide Nasal Spray for COVID-19 in Lancet Journal
– The Lancet Regional Health Southeast Asia publishes the successful phase 3 clinical trial results of Nitric Oxide Nasal Spray.
– Phase 3 trial of Nitric Oxide Nasal Spray administered to adult COVID-19 patients in India met the key endpoints and demonstrated reductions of viral load of 94% in 24 hours and 99% in 48 hours.
– Nitric Oxide Nasal Spray was safe and well tolerated in COVID-19 patients.
– Following positive results and regional approvals, Glenmark launched this nasal spray in India under the brand name FabiSpray® and in Singapore and Hong Kong under the brand name VirX™.
MUMBAI, India and VANCOUVER, BC, July 13, 2022 /PRNewswire/ — Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven, global pharmaceutical company, and SaNOtize Research and Development Corp, today announced that The Lancet Regional Health Southeast Asia (TLRHSEA) – peer reviewed, high impact journal published the successful phase 3 clinical trial results of SaNOtize’s Nitric Oxide Nasal Spray (NONS) study titled: ‘SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial’.
https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(22)00046-4/fulltext
“We are excited to publish the study of the novel Nitric Oxide Nasal Spray, which positively impacts the lives of people, in The Lancet group of journals. The robust double-blind trial demonstrated significant efficacy and remarkable safety of NONS. This therapy has the potential to make a crucial contribution to COVID-19 management, with its ease of use in the current highly transmissible phase of pandemic,” said Dr. Monika Tandon, Senior VP & Head – Clinical Development, Glenmark Pharmaceuticals Ltd.
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment. Viral load was reduced by 93.7% within 24 hours and by 99% within 48 hours of treatment with NONS. The average change from baseline in log viral RNA load through the entire treatment duration was statistically superior with NONS compared to placebo. Similar results were observed in vaccinated and unvaccinated populations. The study was conducted during the delta and omicron surges. Key secondary endpoints including clinical improvement assessed by WHO Clinical Progression Scale Score and extent/rapidity of virologic recovery was demonstrated in patients using NONS. The median time to virological cure was three days in the NONS group and seven days in the placebo group after start of treatment (four days sooner). The exploratory evaluation of the proportion of immediate contacts having a positive COVID-19 test or becoming symptomatic, remained nearly the same in the NONS group while it numerically increased in the placebo group over the treatment.
“The Phase 3 study results strongly support the safety and efficacy of NONS in the treatment of COVID-19 and its known variants,” said Gilly Regev, PhD, SaNOtize Co-Founder and CEO. “Nitric oxide blocks entry into the nasal passage, kills the virus, and stops its replication, which is why viral load is reduced so rapidly with NONS. Viral load has been linked to infectivity, poorer health outcomes, and complications from long COVID. The evidence is mounting that NONS represents an effective, well tolerated antiviral treatment that significantly shortens the course of COVID-19.”
Study Design
The study was conducted by Glenmark in 306 vaccinated and non-vaccinated adults of symptomatic mild COVID-19 across 20 clinical sites in India. This randomized, double-blind phase 3 clinical trial evaluated a seven-day treatment of NONS plus standard of care versus placebo nasal spray plus standard care in patients with symptomatic COVID-19. The primary outcome measure of nasal SARS-CoV-2 RNA accelerated clearance was used to assess the efficacy of this transformational NONS in high-risk patients (unvaccinated, or 45 years of age, or had one or more comorbidities) after seven days of treatment. Exploratory evaluation of NONS in prevention of infection in immediate contacts of these COVID-19 patients was also evaluated.
NONS treatment was found to be well tolerated, establishing an advantage of locally acting nasal therapy. None of the patients reported any moderate or severe adverse events. There were no clinically significant changes from baseline observed in methemoglobin suggesting lack of systemic availability of nitric oxide from nasal spray. Additionally, neither nasal vasodilation symptoms nor systemic vasodilation signs were observed in either treatment.
Strategic Partnership with SaNOtize
In July 2021, Glenmark entered into an exclusive long term strategic partnership with Canadian biotech firm SaNOtize, to manufacture, market and distribute its breakthrough Nitric Oxide Nasal Spray for COVID-19 treatment in India and other Asian markets including Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam.
Global Approvals for NONS
Glenmark launched NONS under the brand name FabiSpray® in February 2022, after receiving manufacturing and marketing approval from the Drugs Controller General of India (DCGI) as part of the accelerated approval process. NONS has already received a CE mark in Europe, which is an equivalent of marketing authorization in case of a Medical Device. By virtue of the CE mark, SaNOtize has permission to launch NONS in the EU. NONS is also approved and being sold in Singapore, Hong Kong, Israel, Thailand, Indonesia and Bahrain, under the name enovid™ or VirX™. Outside of India, NONS has also been approved globally for protection against viruses, including SARS COV-2.
About Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an innovation-driven global pharmaceutical company with a presence across Specialty, Generics and OTC businesses. It focuses on the key therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. Glenmark is ranked among the world’s top 100 biopharmaceutical companies (Top 100 Companies Ranked by Pharmaceutical Sales, 2020, by In Vivo/Scrip 100) and among the world’s top 50 companies in the off-patent sector (Top 50 Generics and Biosimilars Companies ranked by Sales, 2020, by Generics Bulletin/In Vivo). The company was listed on the Dow Jones Sustainability Index (DJSI), one of the world’s most respected and widely accepted sustainability benchmarks, under the category of emerging markets (2021) for the fourth consecutive year. For more information, visit www.glenmarkpharma.com.
Follow us on Social Media:
LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma)
About SaNOtize
SaNOtize Research & Development Corp. is a pharmaceutical company based in Vancouver, BC, commercializing the multi-faceted antimicrobial properties of a liquid producing nitric oxide. The company has developed and patented a Nitric Oxide Releasing Solution platform technology (NORS™) to treat and prevent upper respiratory and topical infections. For more information, visit www.SaNOtize.com. Follow us on social: LinkedIn, Twitter.
News Wire
Reliance Digital Introduces High-Performance iQOO 15R to its Nationwide Store Network
MUMBAI, India, March 11, 2026 /PRNewswire/ — Reliance Digital announces the offline retail availability of iQOO, the high-performance smartphone brand built for today’s youth and tech-forward consumers. Following strong traction in online channels, iQOO is now extending its presence into physical retail, allowing customers to experience and purchase its devices first-hand at Reliance Digital stores across India.
Known for pushing the boundaries of speed, and power, the iQOO 15R is powered by the Snapdragon 8 Gen 5, delivering exceptional speed, responsiveness, and sustained performance throughout the day. It packs iQOO’s biggest battery yet in an ultra-slim 7.90mm design, making it India’s slimmest smartphone with a 7600 mAh battery.
The device features a 6.5K IceCore VC Cooling Chamber for stable performance and runs on OriginOS 6.0 based on Android 16 out of the box, supported by 4 years of software updates and 6 years of security updates. It is also equipped with a Sony LYT-700V OIS camera, a 1.5K 144Hz AMOLED EyeCare display, and IP68 & IP69 dust and water resistance, making it a dependable daily partner for professionals on the go.
The brand’s offline expansion marks an important step in deepening consumer engagement by offering hands-on access to its devices, enabling customers to explore iQOO’s powerful performance, advanced display technology, and flagship-grade camera capabilities in a real-world retail environment.
The availability of iQOO at Reliance Digital brings together two brands driven by innovation and consumer experience. While iQOO continues to build its reputation as a performance-led smartphone brand, Reliance Digital strengthens its portfolio by offering customers access to cutting-edge technology brands through its extensive nationwide retail network.
Through engaging in-store experiences, knowledgeable staff, and immersive product demonstrations, Reliance Digital aims to help consumers better understand iQOO’s performance-first DNA. This move further reinforces Reliance Digital’s commitment to staying ahead of evolving consumer preferences and serving as a preferred destination for discovering new-age technology.
With this expansion, Reliance Digital continues to play a key role in shaping India’s consumer electronics landscape by bringing future-ready brands closer to customers, while enabling smartphone brands like iQOO to build stronger connections with a growing, performance-driven audience.
The all new iQOO 15R is now available at Reliance Digital stores nationwide.
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/reliance-digital-introduces-high-performance-iqoo-15r-to-its-nationwide-store-network-302711079.html
News Wire
Kotak Alts announces winner of the inaugural Katalyst Awards
Ms Himani Choudhary named Katalyst for the year – India’s Best Financial Content Creator; wins Rs. 25 Lakhs
MUMBAI, India, March 10, 2026 /PRNewswire/ — Kotak Katalyst Awards, a national initiative instituted to recognise excellence and responsibility in financial content creation has announced the winner of its first Katalyst edition. Kotak Alternate Asset Managers Limited (“Kotak Alts”) today announced Himani Choudhary as the winner. The winner was awarded a prize of INR 25 Lakhs, positioning Katalyst among the most meaningful recognitions for financial content creators in India.
Srini Sriniwasan, Managing Director, Kotak Alts, said, “The Kotak Alts Katalyst Awards were instituted to recognize content creators who are contributing meaningfully to financial literacy in India. As investor participation deepens, audiences are seeking clarity, context, and credibility. The response from creators was overwhelming and points to the new generation of financial educators. As the inaugural winner Ms. Himani Chaudhary, exemplifies the standard of financial communication that Katalyst seeks to encourage.”
The first edition of the Kotak Alts Katalyst Awards received over six hundred entries from across 19 states and in 8 languages, reflecting the growing role of digital creators in shaping financial awareness. Conceived in response to increasing clutter and misinformation in the financial ecosystem, Katalyst is designed to recognize creators who place accuracy, transparency, and investor interest at the core of their work.
The winning content, ‘Personal Finance & Major Finance Updates’ by Himani Choudhary, was recognised for its clarity, originality, and credibility. The jury noted the content’s ability to explain complex financial concepts in a clear and measured manner, supported by strong research and a consistent focus on investor education over virality.
To ensure a robust and transparent evaluation process, the awards framework was designed and audited by EY. The top thirty entries were assessed by an academic jury.
The top 10 finalists were subsequently evaluated by a grand jury comprising Kunal Shah, Founder and CEO of CRED; Radhika Gupta, Managing Director and CEO of Edelweiss Mutual Fund; and Alpesh Shah, Managing Director and Senior Partner at Boston Consulting Group, and chaired by Ananth Narayan, former Whole–Time Member of SEBI with extensive capital markets and regulatory experience.
The Katalyst Awards recognise financial content creators who priorities financial literacy, substance, and long–term investor interest. Through this initiative, Kotak Alts aims to encourage responsible financial communication and support the development of informed and confident investors across India.
About Kotak Alternate Asset Managers Ltd: Kotak Alternate Asset Managers Limited (‘Kotak Alts’), a part of Kotak Mahindra Group (‘Kotak’), focuses on Alternate Asset Management and Investment Advisory businesses. Kotak Alts was set up in early 2005 and has raised, managed, and advised over USD 22 billion across different asset classes, including Private Equity, Real Estate, Infrastructure, Special Situations, Private Credit, and Investment Advisory. The asset management business and investment advisory vertical are managed by independent specialist teams. For more information, visit https://www.kotakalternateasset.com/
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/kotak-alts-announces-winner-of-the-inaugural-katalyst-awards-302709187.html
News Wire
Paperpal for Life Sciences Establishes HIPAA Readiness, Strengthening Enterprise Adoption of AI in Regulated Medical and Scientific Writing Workflows
MUMBAI, India, March 10, 2026 /PRNewswire/ — Paperpal for Life Sciences, an enterprise-grade Artificial Intelligence (AI) platform by Cactus Communications, purpose-built for Medical Affairs and Life Sciences organizations, announced the completion of an assessment evaluating its operational and technical safeguards to support Health Insurance Portability and Accountability Act (HIPAA) requirements. This milestone reinforces Paperpal’s commitment to meeting the rigorous standards of security, data protection, and regulatory readiness required for regulated scientific workflows.
Growing AI use in medical affairs writing and publication workflows is intensifying scrutiny on data privacy, governance, and regulatory accountability. To support these evolving needs, Paperpal for Life Sciences has undertaken an assessment of its systems and processes to evaluate readiness to support HIPAA compliance, where applicable, and now proudly offers the option to execute a Business Associate Agreement (BAA) for Protected Health Information (PHI) and Personally Identifiable Information (PII). This offering gives customers the confidence that PHI or PII, if received, is handled securely and responsibly, in line with regulatory expectations and enterprise risk management practices.
Paperpal for Life Sciences provides AI writing, literature search, source-grounded summarization with citation support, and critical publication checks, powering medical affairs content creation under stringent data privacy and governance controls. The platform accelerates research-to-publication timelines by upto 25%, supporting faster dissemination of clinical evidence and earlier commercialization of new drugs and therapies.
Nishchay Shah, Group CTO and EVP, Products and AI at Cactus Communications, said, “As AI becomes foundational to regulated scientific and medical workflows, compliance and trust are no longer optional. Paperpal for Life Sciences’ HIPAA readiness measures reflect our secure-by-design approach to AI, strong data governance framework, and alignment with real-world enterprise and regulatory requirements. This milestone enables organizations to adopt AI at scale with confidence that their data, processes, and compliance obligations are protected .”
Elvira Dsouza, President, Cactus Life Sciences, added, “Medical Affairs and Life Sciences teams operate in highly regulated environments where scientific rigor, data privacy, and compliance are non-negotiable. HIPAA readiness positions Paperpal for Life Sciences as a trusted AI partner, one that enables organizations to accelerate evidence generation and scientific communication without compromising regulatory integrity .”
With this announcement, Paperpal for Life Sciences reinforces its position as a purpose-built, enterprise-ready AI platform for medical affairs content generation that supports innovation while meeting the highest standards of privacy, ethics, and regulatory compliance.
Media Contact:
Nidhi Amin
nidhi.amin@cactusglobal.com
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/paperpal-for-life-sciences-establishes-hipaa-readiness-strengthening-enterprise-adoption-of-ai-in-regulated-medical-and-scientific-writing-workflows-302708082.html
India Emerging as Stable Investment Anchor in Turbulent Global Economy, Say Investors at IGF Mumbai 2026
Reliance Digital Introduces High-Performance iQOO 15R to its Nationwide Store Network
Reliance Digital Introduces High-Performance iQOO 15R to its Nationwide Store Network
-
Buzz2 months agoGLOBAL PAY – A New Era in Oman’s Digital Payments Solution
-
Buzz1 month agoCASA BACARDÍ unveils its first Tropical Edition in Goa, celebrating music, culture and collective expression
-
Buzz2 months agoOTM 2026 Set to Bring the Global Travel Industry to Mumbai as India’s Outbound Market Accelerates
-
Buzz1 month agoNew report from Standard Chartered highlights optimistic corporate outlook on India’s energy transition
-
Buzz3 weeks ago70% of Indian Firms Say Cross-Border Trade Has Become Harder to Navigate
-
Buzz1 month ago‘Made in India – The story of Desh Bandhu Gupta, Lupin and Indian Pharma’ Book Launched in Mumbai
-
News Wire1 month agoShriram Life Insurance launches Zaroorat Jaisi, Policy Vaisi: A Fully AI-Created Ad Film Campaign featuring Rahul Dravid
-
News Wire3 weeks agosuper.money Emerges as Market Disruptor, Named India’s Fastest Growing Payments App
You must be logged in to post a comment Login